A Pilot Study of Exenatide Actions in Alzheimer's Disease

BACKGROUND: Strong preclinical evidence suggests that exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist used for treating type 2 diabetes, is neuroprotective and disease-modifying in Alzheimer’s Disease (AD). OBJECTIVE: We performed an 18-month double-blind randomized placebo-controlled...

詳細記述

保存先:
書誌詳細
出版年:Curr Alzheimer Res
主要な著者: Mullins, Roger J., Mustapic, Maja, Chia, Chee W., Carlson, Olga, Gulyani, Seema, Tran, Joyce, Li, Yazhou, Mattson, Mark P., Resnick, Susan, Egan, Josephine M., Greig, Nigel H., Kapogiannis, Dimitrios
フォーマット: Artigo
言語:Inglês
出版事項: 2019
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7476877/
https://ncbi.nlm.nih.gov/pubmed/31518224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1567205016666190913155950
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料